Becton, Dickinson and Company (BDX) Shares Bought by Reinhart Partners Inc.

Reinhart Partners Inc. boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,986 shares of the medical instruments supplier’s stock after buying an additional 21 shares during the period. Reinhart Partners Inc.’s holdings in Becton, Dickinson and were worth $387,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Dodge & Cox bought a new stake in shares of Becton, Dickinson and during the fourth quarter valued at approximately $2,290,000. Quadrature Capital Ltd bought a new stake in shares of Becton, Dickinson and during the fourth quarter valued at approximately $944,000. UBS Asset Management Americas Inc. raised its stake in shares of Becton, Dickinson and by 6.1% in the fourth quarter. UBS Asset Management Americas Inc. now owns 802,950 shares of the medical instruments supplier’s stock valued at $132,928,000 after buying an additional 46,415 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of Becton, Dickinson and by 1.8% in the fourth quarter. Teachers Advisors LLC now owns 346,573 shares of the medical instruments supplier’s stock valued at $57,375,000 after buying an additional 5,995 shares during the last quarter. Finally, Kentucky Retirement Systems bought a new stake in shares of Becton, Dickinson and during the fourth quarter valued at approximately $2,551,000. 75.61% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company (NYSE:BDX) opened at 197.05 on Friday. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63. The firm has a 50-day moving average of $197.67 and a 200-day moving average of $186.53. The firm has a market cap of $42.03 billion, a PE ratio of 32.73 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 26.07% and a net margin of 6.25%. The firm’s revenue was down 5.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.35 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post $9.45 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be issued a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.48%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is 83.43%.

WARNING: This report was reported by [[site]] and is the sole property of of [[site]]. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at [[permalink]].

BDX has been the subject of a number of research reports. BidaskClub lowered shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research lowered shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, May 4th. Bank of America Corporation reaffirmed a “buy” rating and set a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and dropped their target price for the stock from $210.00 to $180.00 in a report on Friday, June 30th. Finally, Evercore ISI raised shares of Becton, Dickinson and from an “in-line” rating to an “outperform” rating and boosted their price target for the company from $186.00 to $200.00 in a research report on Monday, April 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $194.69.

In other Becton, Dickinson and news, VP Jeffrey S. Sherman sold 28,765 shares of Becton, Dickinson and stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $185.98, for a total value of $5,349,714.70. Following the completion of the sale, the vice president now owns 70,821 shares in the company, valued at approximately $13,171,289.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.40% of the stock is owned by insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.